Canigen DHP

Страна: Великобритания

Език: английски

Източник: VMD (Veterinary Medicines Directorate)

Активна съставка:

Canine adenovirus, Canine distemper virus, Canine parvovirus

Предлага се от:

MSD Animal Health UK Limited

АТС код:

QI07AD02

INN (Международно Name):

Canine adenovirus, Canine distemper virus, Canine parvovirus

Лекарствена форма:

Lyophilisate for suspension for injection

Вид предписание :

POM-V - Prescription Only Medicine – Veterinarian

Терапевтична група:

Dogs

Терапевтична област:

Live Viral Vaccine

Статус Оторизация:

Authorized

Дата Оторизация:

2006-04-21

Данни за продукта

Revised: October 2022
AN: 02716/2021
Page 1 of 5
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Canigen DHP lyophilisate and solvent for suspension for injection.
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each 1 ml dose of reconstituted vaccine contains:
ACTIVE SUBSTANCES:
Canine distemper virus, strain Onderstepoort
≥ 10
4.0
TCID
50*
Canine adenovirus 2, strain Manhattan LPV3
≥ 10
4.0
TCID
50*
Canine parvovirus, strain 154
≥ 10
7.0
TCID
50*
*Tissue culture infective dose 50%
Solvent (1 ml per vial):
Phosphate buffered saline.
EXCIPIENTS:
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Lyophilisate and solvent for suspension for injection.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Dogs.
4.2
INDICATIONS FOR USE, SPECIFYING TARGET SPECIES
For the active immunisation of dogs to reduce clinical signs of
disease caused by canine
distemper virus infection; to prevent clinical signs and viral
excretion caused by canine
parvovirus infection; to reduce clinical signs of canine contagious
hepatitis and viral
excretion due to canine adenovirus 1 infection and to reduce clinical
signs of respiratory
infection and viral excretion caused by adenovirus type 2 infection.
_Onset of immunity:_ one week.
_Duration of immunity:_ three years.
4.3
CONTRAINDICATIONS
None.
Revised: October 2022
AN: 02716/2021
Page 2 of 5
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
The efficacy of the CDV, CAV2 and CPV components of the vaccine may be
reduced due
to maternal antibody interference. However, the vaccine has been
proved to be of benefit
against virulent challenge in the presence of maternal antibody levels
to CDV, CAV2 and
CPV that are likely to be encountered under field conditions.
4.5
SPECIAL PRECAUTIONS FOR USE
Special precautions for use in animals:
Only healthy dogs should be vaccinated. Dogs should not be exposed to
unnecessary risk
of infection within the first 2 weeks after completion of the
vaccination regimen.
While the canine parvovirus vaccine strain may be shed